However, it becomes evident from clinical trials that JAK2 inhibitor treatment has limited effect on disease-driving stem cells and thus, it is unlikely that these inhibitors induce complete remission in MPN patients (Pandey et al., 2022). This evidence concerns the gene JAK2 and myeloproliferative neoplasm.